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α-Methylacyl-CoA racemase (AMACR; P504S) catalyses 
‘racemization’ of 2-methylacyl-CoAs, the activation of R-
ibuprofen and is a promising cancer drug target. Human 
recombinant AMACR 1A catalyses elimination of 3-fluoro-2-10 
methyldecanoyl-CoAs to give E-2-methyldec-2-enoyl-CoA 
and fluoride anion, a previously unknown reaction. 
‘Racemization’ of 2-methyldec-3-enoyl-CoAs was also 
catalysed, without double bond migration. 
α-Methylacyl-CoA racemase (AMACR, P504S; E.C. 5.1.99.4) 15 
catalyses the key ‘racemization’† step in the degradation of 
branched-chain fatty acids and is also important in the 
pharmacological activation of R-ibuprofen and related drugs.1-3 
The enzyme catalyses the conversion of either epimer of a 2-
methylacyl-CoA ester to a ca. 1:1 mixture of 2R- and 2S- 20 
epimers.4 AMACR has also been proposed to be involved in the 
uni-directional chiral inversion of mandelic acid in mammals5 but 
this was recently shown to proceed by a distinct pathway.6  
 AMACR protein levels and enzyme activity are increased in 
prostate cancers7,8 a subset of colon cancers9 and various other 25 
cancers1 and it is widely recognised as a promising new drug 
target.1,2,10,11 However, relatively few chemical inhibitors of 
AMACR have been reported,12-15 largely due to the lack of a 
convenient, high-throughput assay.  
 No X-ray crystal structure for a mammalian AMACR has been 30 
reported but the enzyme is proposed to catalyse its reaction by 
removal of the α-proton by Asp-152 or the His-122/Glu-237 
pair1,2,4,16,17 to form an enolate intermediate.18 Non-
stereoselective reprotonation of the enolate gives a ~1:1 mixture 
of 2-methylacyl-CoAs with the original and epimeric 35 
configuration at the -carbon.2,4 Enolates are common 
intermediates in a number of enzymatic reactions, including 
condensations,19 double-bond migrations20 and elimination 
reactions,21 and AMACR could potentially perform these 
reactions with the appropriate substrates. This communication 40 
reports that human recombinant AMACR 1A4 is able to catalyse 
an elimination reaction with 3-fluoro-2-methylacyl-CoA 
substrates to give the corresponding unsaturated 2-methylacyl-
CoA ester and a fluoride anion.22 It is also able to catalyse 
‘racemization’ of unsaturated 2-methylacyl-CoA esters but does 45 
not catalyse migration of the double bond.  
 The known substrate 2-methyldecanoyl-CoA 1S allows the 
course of the enzyme reaction to be followed using 
proton/deuterium exchange in 2H2O. However this assay only 
yields information on exchange of the α-proton; to obtain 50 
information on the stereochemistry a time consuming and scale-
limited derivatisation of products is needed. It was hoped that 
using fluorinated analogues of 2-methylacyl-CoA esters would 
overcome this problem. Specifically syn- and anti- 3-fluoro-2-
methyldecanoyl-CoA, 2S and 2R, were chosen as it was 55 
anticipated that chiral inversion and α-proton exchange of this 
epimeric pair of substrates could be directly and simultaneously 
observed by changes in the 1H and 19F NMR spectra. S- and R- E-
2-methyldec-3-enoyl-CoAs 3S and 3R were chosen as substrates 
in order to test whether AMACR could catalyse double bond 60 
migration into conjugation with the carbonyl group, whilst E-2-
methyldec-2-enoyl-CoA 4 was selected as the proposed product 
of this reaction.  
 
Fig. 1 Structures of the acyl-CoA substrates incubated with human 65 
recombinant AMACR 1A  
 The required substrates were synthesised by extension of 
reported methods.3,4,12 Anti-3-fluoro-2-methyldecanoic acid 5 was 
synthesised by the method of Carnell et al.12 using octanal (ESI, 
Scheme S2). Syn-3-fluoro-2-methyldecanoic acid 6 was 70 
synthesised by aldol reaction of N-propanoyl- Evans’ auxiliary 
with 2-octenal, followed by hydrogenation, conversion to the 
methyl ester, treatment with DAST12 and deprotection (ESI, 
Scheme S3). S- and R-2-methyldec-3-enoic acids 7 were 
synthesised by reaction of the Grignard reagent derived from E-1-75 
crotyl chloride 8 with CO2, followed by chiral resolution of the 
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resulting acids as the N-acylated R-Evans’ auxiliary derivatives. 
Metathesis with 1-octene and deprotection gave the required 
unsaturated acids (ESI, Scheme S4). 2-Methyldec-2-enoic acid 9 
was synthesised by a Wittig reaction between octanal and the 
ylide derived from ethyl 2-bromopropanoate and Ph3P, followed 5 
by deprotection (ESI, Scheme S5). These acids were converted 
into their corresponding acyl-CoA esters by activation with N,N’-
carbonyldiimidazole followed by reaction with CoA-SH.3 
 Initially, acyl-CoA esters were incubated with human 
recombinant AMACR 1A4 in the presence of 2H2O. Incubation of 10 
2R and 2S with active AMACR was expected to result in 
formation of a mixture of epimers at carbon-2 with exchange of 
the α-proton for deuterium resulting in formation of a broad 
single peak (2-bond coupling to the 2H is not normally observed). 
Unexpectedly, the peak at ca. 1.1 ppm diminished with time (Fig. 15 
2) and a new singlet at ca. 1.75 ppm simultaneously arose and 
increased in intensity. In the 19F spectrum the signal for 2R and 
2S slowly disappeared and a new signal appeared at  -122 ppm, 
which is characteristic of inorganic fluoride. Taken together these 
observations suggested that an elimination reaction had occurred. 20 
Product levels increased over time when 2S or 2R were incubated 
with active AMACR (ESI, Figure S1). For 2R, this reaction was 
not observed in negative controls containing heat-inactivated 
enzyme.  
 25 
Fig 2. 1H NMR spectrum of 2R when incubated with AMACR over time 
 Comparison of the 1H NMR spectrum of the unsaturated acyl-
CoA product from the enzymatic elimination reaction showed 
that it was identical to 4. Compound 4 had been synthesised from 
the corresponding E-acid, as assigned by the alkene proton signal 30 
at  6.92 ppm (The Z- acid alkene proton appears at 6.09 ppm).23 
This shows that the geometry of the double bond of the precursor 
acid can be assigned and confirms that the product of the 
enzymatic reaction is the E- isomer. 
  Both 2S and 2R gave the same E- acid product 4, consistent 35 
with an E1cb mechanism21 in which an enolate intermediate18 is 
used to expel the fluoride. The resulting E-double bond suggests 
that the reaction occurs with the substrate in an anti-conformation 
with respect to the -proton and fluoride. This contrasts with 
enoyl-CoA hydratase,21,24 which catalyses its E1cb reaction with 40 
syn-elimination because the two catalytic glutamate residues are 
on the same face of the substrate.24 Anti- elimination by AMACR 
probably results from the combination of a number of factors:21 
Firstly, the substrate side-chain is bound by a hydrophobic 
surface,17 allowing adoption of the more favourable anti- 45 
conformation; secondly, fluorine is a relatively small 
substituent;25 and third, fluoride is likely to be highly solvated in 
aqueous solution. Work in chemical systems suggests that 
fluoride is eliminated by an E1cb-like E2 mechanism26,27 with 
anti- stereochemistry. It is also notable that other enzymes with 50 
enolate or enediol intermediates also eliminate HF from substrate 
analogues, including butyryl-CoA dehydrogenase,28 uronate 
isomerase29 and glyoxylase I.30 Some of these enzymes28,29 also 
possess active-site aspartate or glutamate residues acting as bases.  
 Kinetic analysis of the AMACR-catalysed elimination reaction 55 
showed that Michaelis-Menten behaviour was observed. The 
following kinetic parameters were determined for 2R by the 
Direct Linear Plot:31,32 Km = 21 µM; Vmax = 96.5 nmol.min-1.mg 
protein-1; kcat = 0.0758 s-1; kcat/Km = 3612 M-1 s-1. This compares 
to Km = 277 µM; Vmax = 39.3 nmol.min-1.mg-1 protein; kcat = 60 
0.0310 s-1; kcat/Km = 112 M-1 s-1 for S-2-methyldecanoyl-CoA 1S,3 
implying that the elimination reaction is ~32 more efficient than 
the chiral inversion reaction (as judged by kcat/Km). This is 
probably due to the electron-withdrawing effect of the fluorine 
atom increasing the α-proton acidity.12 For 2S, significant 65 
background conversion was observed in negative controls, 
probably due to the anti- arrangement of the -proton and 
fluorine atom in a favourable staggered conformation. The 
following approximate values for kinetic parameters were 
obtained for 2S: Km = 40 µM; Vmax = 50.6 nmol.min-1.mg protein-70 
1; kcat = 0.0397 s-1; kcat/Km = 993 M-1 s-1. 2R needs to adopt a 
gauche conformation for anti- elimination, and hence the 
background non-enzymatic reaction is less favoured. 
 Incubation of 4 with active AMACR in the presence of 
fluoride did not show any conversion to 2, showing that the 75 
elimination reaction is irreversible. Control experiments with ±-
fenoprofenoyl-CoA showed that AMACR was equally active in 
the presence and absence of fluoride anions, showing the enzyme 
was not inactivated. The irreversibility of the elimination of 2 
probably results from the high levels of hydration of the fluoride 80 
anion. Fluoride is also a hard nucleophile making it less likely to 
react with the soft conjugate electrophile.  
 Unsaturated 2-methylacyl-CoA esters were also investigated as 
substrates for AMACR. Incubation of 3S and 3R with active 
AMACR in the presence of 2H2O resulted in -proton exchange, 85 
as judged by conversions of the doublet at  ca. 1.1 (methyl) into 
a broad single peak and of the doublet of doublets at 5.29 ppm 
into a doublet in the 1H NMR spectrum (ESI, Figure S2). 
Exchange of the -proton is required for the chiral inversion of 
substrates by AMACR,3,4 and therefore it is highly likely that 90 
chiral inversion has also taken place. Substrate incubated with 
heat-inactivated enzyme under the same conditions showed no 
changes, showing that AMACR catalyses ‘racemization’ of 
unsaturated substrates. Native human and rat enzymes have been 
previously  reported33,34 not to bind similar unsaturated acyl-CoA 95 
esters (based on a competition assay), suggesting they bind 
relatively weakly compared to saturated substrates.  
 Rearrangement of the double bond of 3S or 3R was not 
catalysed by AMACR, with no formation of 4 as shown by the 
absence of the characteristic methyl group singlet at ca.  1.8 in 100 
the 1H NMR spectrum. These results imply that either no proton 
donor is in close proximity to the distal end of the double bond to 
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facilitate migration or that reprotonation of the enolate 
intermediate18 to give ‘racemization’ is much more efficient.  
 Incubation of the 2-unsaturated acyl-CoA ester 4 with active 
AMACR showed, by 1H NMR analysis, that it was not converted 
to 3 or any other product. It is not clear whether this is due to 4 5 
failing to bind to AMACR or if it binds but does not undergo a 
reaction. It is known that 2-methylene acyl-CoA esters, which 
also possess a sp2-hybridised carbon-2, behave as reversible tight-
binding dead-end inhibitors of human AMACR 1A in vivo,2,13 
suggesting that 4 may also be bound.  10 
 The results in this Communication demonstrate that human 
AMACR 1A is able to catalyse irreversible elimination of 
substrates, probably by an E1cb or E1cb-like E2 mechanism. The 
reaction is of potential utility for measuring the AMACR activity, 
since quantification of both the enoyl-CoA and fluoride products 15 
is possible. It is also notable that several AMACR inhibitors with 
similar structures to 2R and 2S have been reported.12 Given that 
the only difference between these compounds and 2R is the 
length of the side-chain, it is quite possible that these compounds 
also undergo an elimination reaction. Fluorine atoms are often 20 
used in drug molecules (with >20% of all drugs containing at 
least one fluorine atom33), but it is important to consider that they 
may be reactive under certain circumstances. These results also 
extend the range of substrates for the AMACR chiral inversion 
reaction to include 2-methyl-3-enoyl-CoA esters. 25 
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